295 related articles for article (PubMed ID: 34613964)
1. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
[TBL] [Abstract][Full Text] [Related]
2. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA
Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605
[TBL] [Abstract][Full Text] [Related]
3. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.
Bergeron M; Motter R; Tanaka P; Fauss D; Babcock M; Chiou SS; Nelson S; San Pablo F; Anderson JP
Neuroscience; 2014 Jan; 256():72-82. PubMed ID: 24128992
[TBL] [Abstract][Full Text] [Related]
4. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: Research tools for synucleinopathies.
Fayyad M; Majbour NK; Vaikath NN; Erskine D; El-Tarawneh H; Sudhakaran IP; Abdesselem H; El-Agnaf OMA
Neurosci Lett; 2020 Apr; 725():134899. PubMed ID: 32156613
[TBL] [Abstract][Full Text] [Related]
5. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.
Landeck N; Hall H; Ardah MT; Majbour NK; El-Agnaf OM; Halliday G; Kirik D
Mol Neurodegener; 2016 Aug; 11(1):61. PubMed ID: 27549140
[TBL] [Abstract][Full Text] [Related]
6. Genetic deletion of Polo-like kinase 2 reduces alpha-synuclein serine-129 phosphorylation in presynaptic terminals but not Lewy bodies.
Weston LJ; Stackhouse TL; Spinelli KJ; Boutros SW; Rose EP; Osterberg VR; Luk KC; Raber J; Weissman TA; Unni VK
J Biol Chem; 2021; 296():100273. PubMed ID: 33428941
[TBL] [Abstract][Full Text] [Related]
7. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
Oueslati A
J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
[TBL] [Abstract][Full Text] [Related]
8. Investigating the presence of doubly phosphorylated α-synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases.
Fayyad M; Erskine D; Majbour NK; Vaikath NN; Ghanem SS; Sudhakaran IP; Abdesselem H; Lamprokostopoulou A; Vekrellis K; Morris CM; Attems J; El-Agnaf OMA
Brain Pathol; 2020 Jul; 30(4):831-843. PubMed ID: 32324926
[TBL] [Abstract][Full Text] [Related]
9. Behavioral Deficits and Brain α-Synuclein and Phosphorylated Serine-129 α-Synuclein in Male and Female Mice Overexpressing Human α-Synuclein.
Gabrielyan L; Liang H; Minalyan A; Hatami A; John V; Wang L
J Alzheimers Dis; 2021; 79(2):875-893. PubMed ID: 33361597
[TBL] [Abstract][Full Text] [Related]
10. Dynamic reversibility of α-synuclein serine-129 phosphorylation is impaired in synucleinopathy models.
Ramalingam N; Brontesi L; Jin SX; Selkoe DJ; Dettmer U
EMBO Rep; 2023 Dec; 24(12):e57145. PubMed ID: 37870370
[TBL] [Abstract][Full Text] [Related]
11. Specific Detection of Physiological S129 Phosphorylated α-Synuclein in Tissue Using Proximity Ligation Assay.
Arlinghaus R; Iba M; Masliah E; Cookson MR; Landeck N
J Parkinsons Dis; 2023; 13(2):255-270. PubMed ID: 36847016
[TBL] [Abstract][Full Text] [Related]
12. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.
Walker DG; Lue LF; Adler CH; Shill HA; Caviness JN; Sabbagh MN; Akiyama H; Serrano GE; Sue LI; Beach TG;
Exp Neurol; 2013 Feb; 240():190-204. PubMed ID: 23201181
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.
Vaikath NN; Erskine D; Morris CM; Majbour NK; Vekrellis K; Li JY; El-Agnaf OMA
Neuropathol Appl Neurobiol; 2019 Oct; 45(6):597-608. PubMed ID: 30422353
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.
Paleologou KE; Oueslati A; Shakked G; Rospigliosi CC; Kim HY; Lamberto GR; Fernandez CO; Schmid A; Chegini F; Gai WP; Chiappe D; Moniatte M; Schneider BL; Aebischer P; Eliezer D; Zweckstetter M; Masliah E; Lashuel HA
J Neurosci; 2010 Mar; 30(9):3184-98. PubMed ID: 20203178
[TBL] [Abstract][Full Text] [Related]
15. Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo.
Wu J; Lou H; Alerte TN; Stachowski EK; Chen J; Singleton AB; Hamilton RL; Perez RG
Neuroscience; 2012 Apr; 207():288-97. PubMed ID: 22326202
[TBL] [Abstract][Full Text] [Related]
16. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.
Henderson-Smith A; Chow D; Meechoovet B; Aziz M; Jacobson SA; Shill HA; Sabbagh MN; Caviness JN; Adler CH; Driver-Dunckley ED; Beach TG; Yin H; Dunckley T
PLoS One; 2013; 8(10):e77711. PubMed ID: 24204929
[TBL] [Abstract][Full Text] [Related]
17. Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function.
Buck K; Landeck N; Ulusoy A; Majbour NK; El-Agnaf OM; Kirik D
Neurobiol Dis; 2015 Jun; 78():100-14. PubMed ID: 25818009
[TBL] [Abstract][Full Text] [Related]
18. Age- and brain region-dependent α-synuclein oligomerization is attributed to alterations in intrinsic enzymes regulating α-synuclein phosphorylation in aging monkey brains.
Chen M; Yang W; Li X; Li X; Wang P; Yue F; Yang H; Chan P; Yu S
Oncotarget; 2016 Feb; 7(8):8466-80. PubMed ID: 27032368
[TBL] [Abstract][Full Text] [Related]
19. Iron-induced oxidative stress contributes to α-synuclein phosphorylation and up-regulation via polo-like kinase 2 and casein kinase 2.
Wang R; Wang Y; Qu L; Chen B; Jiang H; Song N; Xie J
Neurochem Int; 2019 May; 125():127-135. PubMed ID: 30797969
[TBL] [Abstract][Full Text] [Related]
20. Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model.
Behere A; Thörnqvist PO; Winberg S; Ingelsson M; Bergström J; Ekmark-Lewén S
J Neurosci Res; 2021 Oct; 99(10):2525-2539. PubMed ID: 34292621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
